Core Viewpoint - The collaboration between Shanghai Municipal Market Supervision Administration and Innovent Biologics aims to enhance compliance and risk management in the pharmaceutical industry, supporting innovation and development in the biopharmaceutical sector [1][4]. Group 1: Compliance System Development - A memorandum of understanding was signed to guide the construction of a compliance system for pharmaceutical companies, focusing on five key areas: drug promotion compliance, academic exchange management, drug pricing behavior, distributor management, and protection of commercial secrets [3]. - The collaboration will provide policy guidance and professional support to help companies clarify legal boundaries, improve internal control mechanisms, and mitigate legal risks [3]. Group 2: Communication and Cooperation Mechanism - A "regular, multi-level, and high-efficiency" communication mechanism will be established to enhance information exchange and feedback on issues through various methods, including policy consultation, risk alerts, and compliance training [3]. - This partnership is seen as a significant step towards a proactive compliance approach, moving from "passive compliance" to "active compliance" in the pharmaceutical sector [4]. Group 3: Industry Impact - The initiative is part of a broader effort to create a fair and orderly pharmaceutical market environment, contributing to the high-quality development of Shanghai's biopharmaceutical industry [4]. - The collaboration is expected to serve as a model for further compliance initiatives in the pharmaceutical field, promoting replicable and scalable practices [4].
从 “被动合规” 到 “主动合规” 上海政企共建推动医药产业合规升级